GHRP-6

GHRP-6 is a linear hexapeptide containing D-amino-acid residues that confer enzymatic stability while retaining affinity for the growth-hormone secretagogue receptor type 1a (GHS-R1a). The molecule engages the same Gq/PLC calcium-signaling cascade documented for the endogenous ligand ghrelin and other GHRP-class compounds. Relative to later-generation GHRP-class peptides, the literature also describes a documented appetite-pathway interaction profile that distinguishes GHRP-6 from more selectively GH-targeted analogs such as ipamorelin. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and a short systemic half-life under standard parenteral paradigms. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation is established by mass spectrometry and HPLC-validated purity on each Certificate of Analysis.

Experimental domains documented in the published literature include GHS-R1a receptor-binding studies, comparative GHRP-class structure-activity investigations spanning the original through later-generation hexapeptide secretagogues, somatotroph-cell calcium-signaling assays, ghrelin-pathway appetite-signaling research in animal-model contexts, and feedback-loop modeling in growth-hormone-axis paradigms. Investigators have also characterized GHRP-6 in studies probing the structural determinants of receptor selectivity that distinguish original-generation GHRPs from more selective later-generation analogs. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a comparative reference in GHS-R1a structure-activity work. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C46H56N12O6 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.